BR112023002071A2 - Métodos para preparar nanopartículas lipídicas - Google Patents
Métodos para preparar nanopartículas lipídicasInfo
- Publication number
- BR112023002071A2 BR112023002071A2 BR112023002071A BR112023002071A BR112023002071A2 BR 112023002071 A2 BR112023002071 A2 BR 112023002071A2 BR 112023002071 A BR112023002071 A BR 112023002071A BR 112023002071 A BR112023002071 A BR 112023002071A BR 112023002071 A2 BR112023002071 A2 BR 112023002071A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- lipid nanoparticles
- prepare lipid
- lnp
- relates
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000002105 nanoparticle Substances 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
Abstract
MÉTODOS PARA PREPARAR NANOPARTÍCULAS LIPÍDICAS. A presente invenção refere-se a métodos para produzir formulações de nanopartícula lipídica (LNP) e formulações de LNP produzidas das mesmas. A presente invenção também se refere a usos terapêuticos e diagnósticos relacionados às formulações de LNP produzidas.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063062369P | 2020-08-06 | 2020-08-06 | |
US202163143703P | 2021-01-29 | 2021-01-29 | |
US202163226395P | 2021-07-28 | 2021-07-28 | |
PCT/US2021/044928 WO2022032087A1 (en) | 2020-08-06 | 2021-08-06 | Methods of preparing lipid nanoparticles |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023002071A2 true BR112023002071A2 (pt) | 2023-05-02 |
Family
ID=77519867
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023002071A BR112023002071A2 (pt) | 2020-08-06 | 2021-08-06 | Métodos para preparar nanopartículas lipídicas |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230277457A1 (pt) |
EP (1) | EP4192432A1 (pt) |
JP (1) | JP2023543963A (pt) |
KR (1) | KR20230167008A (pt) |
AU (1) | AU2021322310A1 (pt) |
BR (1) | BR112023002071A2 (pt) |
CA (1) | CA3190790A1 (pt) |
IL (1) | IL300404A (pt) |
MX (1) | MX2023001567A (pt) |
TW (1) | TW202220637A (pt) |
WO (1) | WO2022032087A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112021006539A2 (pt) | 2018-10-09 | 2021-07-06 | Univ British Columbia | composições e sistemas competentes de vesículas competentes para transfecção isentas de solventes e detergentes orgânicos e métodos relacionados às mesmas |
WO2024026487A1 (en) | 2022-07-29 | 2024-02-01 | Modernatx, Inc. | Lipid nanoparticle compositions comprising phospholipid derivatives and related uses |
WO2024026482A1 (en) | 2022-07-29 | 2024-02-01 | Modernatx, Inc. | Lipid nanoparticle compositions comprising surface lipid derivatives and related uses |
WO2024026475A1 (en) | 2022-07-29 | 2024-02-01 | Modernatx, Inc. | Compositions for delivery to hematopoietic stem and progenitor cells (hspcs) and related uses |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2428571B1 (en) | 2001-09-28 | 2018-07-18 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | MicroRNA molecules |
CA2533701A1 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
CA2633754C (en) | 2006-01-05 | 2013-06-18 | The Ohio State University Research Foundation | Microrna-based methods and compositions for the diagnosis and treatment of solid cancers |
EP2591794A1 (en) | 2006-01-05 | 2013-05-15 | The Ohio State University Research Foundation | MicroRNA expressions abnormalities in pancreatic endocrine and acinar tumors |
EP2522749A1 (en) | 2006-03-02 | 2012-11-14 | The Ohio State University | MicroRNA expression profile associated with pancreatic cancer |
EP2115138A2 (en) | 2006-09-19 | 2009-11-11 | Asuragen, Inc. | Micrornas differentially expressed in pancreatic diseases and uses thereof |
WO2008054828A2 (en) | 2006-11-01 | 2008-05-08 | The Ohio State University Research Foundation | Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma |
CN101622348A (zh) | 2006-12-08 | 2010-01-06 | 奥斯瑞根公司 | 作为治疗性干预靶标的miR-20调节的基因和途径 |
WO2008147974A1 (en) | 2007-05-23 | 2008-12-04 | University Of South Florida | Micro-rnas modulating immunity and inflammation |
WO2008154098A2 (en) | 2007-06-07 | 2008-12-18 | Wisconsin Alumni Research Foundation | Reagents and methods for mirna expression analysis and identification of cancer biomarkers |
JP2011505143A (ja) | 2007-11-30 | 2011-02-24 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | マイクロrna発現プロファイリング及び肺癌における末梢血ターゲティング |
WO2009100430A2 (en) | 2008-02-08 | 2009-08-13 | Asuragen, Inc | miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS |
US20110052502A1 (en) | 2008-02-28 | 2011-03-03 | The Ohio State University Research Foundation | MicroRNA Signatures Associated with Human Chronic Lymphocytic Leukemia (CCL) and Uses Thereof |
EP2112235A1 (en) | 2008-04-24 | 2009-10-28 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Compositions and methods for microRNA expression profiling of nasopharyngeal carcinoma |
WO2010018563A2 (en) | 2008-08-12 | 2010-02-18 | Rosetta Genomics Ltd. | Compositions and methods for the prognosis of lymphoma |
US9074206B2 (en) | 2008-11-13 | 2015-07-07 | Fudan University | Compositions and methods for micro-RNA expression profiling of colorectal cancer |
EP2358902A1 (en) | 2008-12-10 | 2011-08-24 | Universität Regensburg | Compositions and methods for micro-rna expression profiling of cancer stem cells |
WO2010129860A2 (en) | 2009-05-08 | 2010-11-11 | The Ohio State University Research Foundation | Microrna expression profiling and targeting in chronic obstructive pulmonary disease (copd) lung tissue and methods of use thereof |
DK2440183T3 (en) | 2009-06-10 | 2018-10-01 | Arbutus Biopharma Corp | Improved lipid formulation |
WO2011076143A1 (en) | 2009-12-24 | 2011-06-30 | Fudan University | Compositions and methods for microrna expression profiling of lung cancer |
WO2011076142A1 (en) | 2009-12-24 | 2011-06-30 | Fudan University | Compositions and methods for microrna expession profiling in plasma of colorectal cancer |
EP2341145A1 (en) | 2009-12-30 | 2011-07-06 | febit holding GmbH | miRNA fingerprint in the diagnosis of diseases |
WO2011094683A2 (en) | 2010-01-29 | 2011-08-04 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Method of identifying myelodysplastic syndromes |
EP2354246A1 (en) | 2010-02-05 | 2011-08-10 | febit holding GmbH | miRNA in the diagnosis of ovarian cancer |
WO2011113030A2 (en) | 2010-03-11 | 2011-09-15 | H.Lee Moffitt Cancer Center & Research Institute | Human cancer micro-rna expression profiles predictive of chemo-response |
WO2011157294A1 (en) | 2010-06-16 | 2011-12-22 | Universita' Degli Studi Di Padova | Compositions for use in treating or preventing cancer, breast cancer, lung cancer, ovarian cancer, metastasis, heart failure, cardiac remodelling, dilated cardiomyopathy, autoimmune diseases, or diseases or disorders related thereto |
WO2012151212A1 (en) | 2011-05-01 | 2012-11-08 | University Of Rochester | Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof |
WO2012153187A2 (en) | 2011-05-06 | 2012-11-15 | Xentech | Markers for cancer prognosis and therapy and methods of use |
DK2718261T3 (en) * | 2011-06-08 | 2016-03-29 | Nitto Denko Corp | Compounds to target drug delivery and promote siRNA activity |
ES2610245T3 (es) | 2011-07-15 | 2017-04-26 | Leo Pharma A/S | Perfilado de microARN para el diagnóstico en linfoma cutáneo de células T (CTCL) |
US20150080243A1 (en) | 2011-09-01 | 2015-03-19 | Allegro Diagnostics Corp. | Methods and compositions for detecting cancer based on mirna expression profiles |
WO2013066678A1 (en) | 2011-10-26 | 2013-05-10 | Georgetown University | Microrna expression profiling of thyroid cancer |
WO2013086373A1 (en) * | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
CA2897941A1 (en) | 2013-01-17 | 2014-07-24 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
CN105143456A (zh) | 2013-03-15 | 2015-12-09 | 不列颠哥伦比亚大学 | 用于转染的脂质纳米粒子和相关方法 |
US10821175B2 (en) | 2014-02-25 | 2020-11-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
US20180256750A1 (en) | 2015-09-17 | 2018-09-13 | Moderna Therapeutics, Inc. | Polynucleotides containing a stabilizing tail region |
AU2016324310B2 (en) | 2015-09-17 | 2021-04-08 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
WO2017062513A1 (en) | 2015-10-05 | 2017-04-13 | Modernatx, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
PL3394030T3 (pl) | 2015-12-22 | 2022-04-11 | Modernatx, Inc. | Związki i kompozycje do wewnątrzkomórkowego dostarczania środków |
CA3055653A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
HUE060693T2 (hu) | 2017-03-15 | 2023-04-28 | Modernatx Inc | Vegyület és készítmények terápiás szerek intracelluláris bejuttatására |
US20210198200A1 (en) | 2017-06-14 | 2021-07-01 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
JP2021528096A (ja) * | 2018-06-28 | 2021-10-21 | アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag | エキソソーム細胞外小胞及びその使用方法 |
CA3113436A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
CA3128215A1 (en) | 2019-01-31 | 2020-08-06 | Modernatx, Inc. | Methods of preparing lipid nanoparticles |
CA3169669A1 (en) * | 2020-01-31 | 2021-08-05 | Modernatx, Inc. | Methods of preparing lipid nanoparticles |
-
2021
- 2021-08-06 MX MX2023001567A patent/MX2023001567A/es unknown
- 2021-08-06 TW TW110129190A patent/TW202220637A/zh unknown
- 2021-08-06 JP JP2023508048A patent/JP2023543963A/ja active Pending
- 2021-08-06 US US18/040,745 patent/US20230277457A1/en active Pending
- 2021-08-06 WO PCT/US2021/044928 patent/WO2022032087A1/en active Application Filing
- 2021-08-06 AU AU2021322310A patent/AU2021322310A1/en active Pending
- 2021-08-06 KR KR1020237007662A patent/KR20230167008A/ko unknown
- 2021-08-06 EP EP21762299.2A patent/EP4192432A1/en active Pending
- 2021-08-06 IL IL300404A patent/IL300404A/en unknown
- 2021-08-06 BR BR112023002071A patent/BR112023002071A2/pt unknown
- 2021-08-06 CA CA3190790A patent/CA3190790A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
TW202220637A (zh) | 2022-06-01 |
KR20230167008A (ko) | 2023-12-07 |
MX2023001567A (es) | 2023-06-28 |
AU2021322310A1 (en) | 2023-04-13 |
IL300404A (en) | 2023-04-01 |
WO2022032087A1 (en) | 2022-02-10 |
US20230277457A1 (en) | 2023-09-07 |
EP4192432A1 (en) | 2023-06-14 |
CA3190790A1 (en) | 2022-02-10 |
JP2023543963A (ja) | 2023-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022014970A2 (pt) | Métodos para preparar nanopartículas lipídicas | |
BR112023002071A2 (pt) | Métodos para preparar nanopartículas lipídicas | |
BR112021014845A2 (pt) | Métodos de preparação de nanopartículas lipídicas | |
AR083561A1 (es) | Preparacion de una construccion antigenica | |
CL2020001478A1 (es) | Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y métodos de uso de estos. | |
BR112018074229A2 (pt) | exossomos compreendendo polipeptídeos terapêuticos | |
WO2018144093A3 (en) | ENHANCED SKIN CARE FORMULATIONS | |
CY1114685T1 (el) | Παρατεταμενη απελευθερωση αντιμολυσματικων αμινογλυκοζιτων | |
BR112012002709A2 (pt) | formulações de liberação controlada de muteínas de lipocalina | |
ECSP21044606A (es) | Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y sus métodos de uso | |
CO6501190A2 (es) | Vacuna de pcsk9 | |
CU20110221A7 (es) | Derivados de 1h-imidazo-[4,5-c]-quinolinona | |
BR112015001782A2 (pt) | método para produzir uma composição para o tratamento de um dente lesionado | |
BR112022013837A2 (pt) | Nanopartículas lipídicas | |
WO2022066898A3 (en) | Methods of producing extracellular vesicles | |
AR123171A1 (es) | Métodos para preparar nanopartículas lipídicas | |
Vyas et al. | A comparative study of dexmedetomidine vs midazolam for sedation and hemodynamic changes during tympanoplasty and modified radical mastoidectomy. | |
PL122243U1 (pl) | Stół operacyjny | |
AR125749A1 (es) | Profármacos lipídicos de psicodélicos de triptamina y fenetilamina y sus usos | |
Parrasia | Composti naturali e loro derivati nella salute e nelle patologie | |
CO2021010157A1 (es) | Estación de entrenamiento para procedimientos quirúrgicos | |
WO2023104114A3 (en) | Rna formulations and lipids | |
GAO et al. | Use of dental operating microscope in non-surgical endodontic treatment | |
WO2023081194A3 (en) | Methods for treating alzheimer's disease | |
AR121798A1 (es) | Vacunas de ácido nucleico contra el coronavirus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: MODERNATX, INC. (US) |